Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

B&L Eyes Zyoptix Per-Procedure Fees To Recoup LASIK Royalties To Visx

This article was originally published in The Gray Sheet

Executive Summary

Bausch & Lomb will look to its Zyoptix eye diagnostic system to eventually offset royalty payments to LASIK competitor Visx.

You may also be interested in...



B&L Looks To Zyoptix, Eyetracking System to Boost Refractive Market Share

Bausch & Lomb will incorporate its Active Eyetracking high-speed image processing system into all Technolas 217A excimer lasers sold after November at no additional cost.

B&L Looks To Zyoptix, Eyetracking System to Boost Refractive Market Share

Bausch & Lomb will incorporate its Active Eyetracking high-speed image processing system into all Technolas 217A excimer lasers sold after November at no additional cost.

Applied Biosystems' Good Genes Boost Stock 56% In 2000; Index Ahead 29%

The untapped possibilities of genetic analysis for early stage detection of disease combined with a nearly completed effort to map the human genome helped breathe new life into the diagnostics sector in 2000, led by Applera Corp. (formerly PE Corp.) and its two component business units, Applied Biosystems and Celera Genomics.

Related Content

UsernamePublicRestriction

Register

MT014550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel